Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.
The FDA’s decision to remove the ‘black box’ warnings from hormone replacement therapies (HRTs) marks a significant regulatory change that is expected to enhance prescribing practices, boost patient and physician confidence, and expand the market for women’s health therapies. This change could reduce stigma and hesitation around HRT, potentially unlocking new patient segments and increasing the utilization of Mayne Pharma’s HRT products, BIJUVA® and IMVEXXY®, thereby driving commercial execution and delivering greater value for patients.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel pharmaceuticals, particularly in dermatology and women’s health in the United States. The company also provides contract development and manufacturing services globally and has a 40-year history of innovation in oral drug delivery systems.
Average Trading Volume: 448,691
Technical Sentiment Signal: Sell
Current Market Cap: A$398.1M
Learn more about MYX stock on TipRanks’ Stock Analysis page.